Insulet Co. (NASDAQ:PODD) Shares Acquired by Aperio Group LLC

Aperio Group LLC grew its position in Insulet Co. (NASDAQ:PODD) by 7.8% in the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 22,510 shares of the medical instruments supplier’s stock after acquiring an additional 1,622 shares during the period. Aperio Group LLC’s holdings in Insulet were worth $5,326,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. DekaBank Deutsche Girozentrale raised its position in shares of Insulet by 8.9% during the 2nd quarter. DekaBank Deutsche Girozentrale now owns 3,883 shares of the medical instruments supplier’s stock worth $724,000 after purchasing an additional 316 shares during the last quarter. Vident Investment Advisory LLC raised its position in shares of Insulet by 167.0% during the 2nd quarter. Vident Investment Advisory LLC now owns 6,239 shares of the medical instruments supplier’s stock worth $1,212,000 after purchasing an additional 3,902 shares during the last quarter. Cerebellum GP LLC acquired a new position in shares of Insulet during the 2nd quarter worth about $122,000. Nissay Asset Management Corp Japan ADV raised its position in shares of Insulet by 10.7% during the 2nd quarter. Nissay Asset Management Corp Japan ADV now owns 6,527 shares of the medical instruments supplier’s stock worth $1,268,000 after purchasing an additional 633 shares during the last quarter. Finally, NN Investment Partners Holdings N.V. acquired a new position in shares of Insulet during the 2nd quarter worth about $1,841,000.

Insulet stock opened at $265.24 on Friday. The firm has a 50 day simple moving average of $245.23 and a 200-day simple moving average of $213.90. Insulet Co. has a 1-year low of $121.00 and a 1-year high of $269.42. The company has a debt-to-equity ratio of 1.62, a current ratio of 8.08 and a quick ratio of 7.31. The stock has a market cap of $17.49 billion, a price-to-earnings ratio of 947.32 and a beta of 0.73.

Insulet (NASDAQ:PODD) last posted its quarterly earnings results on Wednesday, November 4th. The medical instruments supplier reported $0.17 earnings per share for the quarter, beating the consensus estimate of $0.08 by $0.09. Insulet had a net margin of 2.20% and a return on equity of 10.96%. The business had revenue of $234.00 million during the quarter, compared to analysts’ expectations of $221.73 million. During the same quarter in the prior year, the company posted $0.01 EPS. The business’s revenue for the quarter was up 21.9% on a year-over-year basis. Equities analysts expect that Insulet Co. will post 0.33 earnings per share for the current fiscal year.

In other news, COO Charles Alpuche sold 3,415 shares of the company’s stock in a transaction that occurred on Tuesday, September 1st. The shares were sold at an average price of $220.11, for a total value of $751,675.65. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, CEO Shacey Petrovic sold 15,000 shares of the company’s stock in a transaction that occurred on Monday, October 5th. The stock was sold at an average price of $233.91, for a total transaction of $3,508,650.00. Following the completion of the transaction, the chief executive officer now owns 33,813 shares in the company, valued at $7,909,198.83. The disclosure for this sale can be found here. In the last three months, insiders sold 22,415 shares of company stock valued at $5,160,326. Corporate insiders own 1.10% of the company’s stock.

PODD has been the subject of several research analyst reports. UBS Group upped their price target on shares of Insulet from $230.00 to $245.00 and gave the stock a “neutral” rating in a research report on Thursday, November 5th. Oppenheimer restated a “hold” rating and set a $235.00 price target on shares of Insulet in a research report on Friday, August 7th. Citigroup upped their price objective on shares of Insulet from $200.00 to $255.00 and gave the company a “buy” rating in a research note on Friday, August 7th. Raymond James upped their price objective on shares of Insulet from $249.00 to $250.00 and gave the company an “outperform” rating in a research note on Thursday, November 5th. Finally, Canaccord Genuity upped their price objective on shares of Insulet from $210.00 to $240.00 and gave the company a “hold” rating in a research note on Thursday, November 5th. Two equities research analysts have rated the stock with a sell rating, eleven have issued a hold rating and eight have assigned a buy rating to the company. The company presently has an average rating of “Hold” and an average target price of $232.82.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. Its Omnipod System comprise two devices: a self-adhesive disposable tubeless Omnipod device that is worn on the body for up to three days at a time, and its wireless companion, the handheld personal diabetes manager.

Featured Article: What is a Backdoor Roth IRA?

Want to see what other hedge funds are holding PODD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Insulet Co. (NASDAQ:PODD).

Institutional Ownership by Quarter for Insulet (NASDAQ:PODD)

Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with MarketBeat.com's FREE daily email newsletter.